Study shows that blood poisoning drug withdrawn by manufacturer may be effective after all

A controversial drug used to treat patients with severe sepsis (a whole-body inflammatory response often bought on by blood poisoning) withdrawn by manufacturer Eli Lilly in October 2011 due to concerns over its efficacy may offer some benefit to patients after all, according to a new systematic review of the evidence published in the Lancet Infectious Diseases.

The drug, called drotrecogin alfa (activated) and marketed by manufacturer Eli Lilly as Xigris, was approved for use in the United States in 2001, and in Europe in 2002, on the basis of the randomised, double-blind, placebo-controlled PROWESS study.

However, concerns were raised over the drug's efficacy and side-effects, and a second clinical study (PROWESS-SHOCK) led to Eli Lilly withdrawing the drug in October 2011, with the US FDA () making a Safety Announcement in which it stated that drotrecogin alfa (activated) treatment should be stopped in patients being treated with the drug, and no new patients should be prescribed the drug.

The Article published today [Monday, July 16] examines real-life usage of the drug over a period of ten years, and concludes that the efficacy of Xigris is, in fact, comparable to that suggested by the original PROWESS trial. Use of the drug was associated with an 18% reduction in the relative risk of death in hospital for with severe sepsis, and the authors found no significant differences between the mortality reductions reported by industry-sponsored and independent controlled studies.

According to the study's authors, Dr Andre Kalil of the University of Nebraska Medical Center, USA, and Dr Steven LaRosa of Beverly Hospital, USA, "Compared with the PROWESS trial, real-life use of drotrecogin alfa (activated) was associated with…a similar and significant reduction in the risk of death…Our effectiveness findings accord with PROWESS but not with the PROWESS-SHOCK trial."

Dr Jean-Louis Vincent of the Free University of Brussels, the author of a linked Comment published alongside the Article, said: "Although these data might not represent the highest levels of evidence, many of us (including me) maintain that we can learn a lot from such real-life studies. The death rate from sepsis is unacceptable and new drugs are needed urgently, so one might ask whether drotrecogin alfa (activated) can be resurrected. However, unfortunately Eli Lilly has given up and the cannot be produced easily."*

More information:
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Risk said associated with Eli Lilly drug

Nov 05, 2007

A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments